Subscribe Us

header ads

Recents

header ads

US Liquid Biopsy Market Size At Around US$ 362.82 Bn In 2030

The US liquid biopsy market would grow at a CAGR of 17.48% over the predicted time frame. The market is expected to increase in value from US$ 362.82 Mn in 2022 to US$ 1,816.95 Mn in 2032.

US Liquid Biopsy Market Size 2023 To 2032

The on US liquid biopsy Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/2474

A recent report provides crucial insights along with application based and forecast information in the Global US liquid biopsy Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the US liquid biopsy market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global US liquid biopsy market are included as given below:

US liquid biopsy Market Key Players

  • ANGLE plc, Biocept Inc.
  • Bio-Rad Laboratories Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • Guardant Health Inc. 
  • Illumina Inc.
  • MDxHealth SA 
  • Menarini Silicon Biosystems
  • QIAGEN N.V. 
  • Thermo Fisher Scientific Inc.

Market Segments

By Biomarker Types 

  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (CTDNA)
  • Extracellular vesicles (EVS)
  • Other Biomarkers

By Application 

  • Cancer Therapeutic Application
  • Reproductive Health
  • Other Therapeutic Application

By Sample 

  • Blood Sample
  • Urine Sample 
  • Other

By End User 

  • Hospitals and Laboratories
  • Academic and Research Centers
  • Other End Users

Report Objectives

  • To define, describe, and forecast the global US liquid biopsy market based on product, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
  • To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the US liquid biopsy market

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on US Liquid Biopsy Market 

5.1. COVID-19 Landscape: US Liquid Biopsy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. US Liquid Biopsy Market, By Biomarker Types

8.1. US Liquid Biopsy Market, by Biomarker Types, 2022-2032

8.1.1. Circulating Tumor Cells (CTCs)

8.1.1.1. Market Revenue and Forecast (2022-2032)

8.1.2. Circulating Tumor DNA (CTDNA)

8.1.2.1. Market Revenue and Forecast (2022-2032)

8.1.3. Extracellular vesicles (EVS)

8.1.3.1. Market Revenue and Forecast (2022-2032)

8.1.4. Other Biomarkers

8.1.4.1. Market Revenue and Forecast (2022-2032)

Chapter 9. US Liquid Biopsy Market, By Application

9.1. US Liquid Biopsy Market, by Application, 2022-2032

9.1.1. Cancer Therapeutic Application

9.1.1.1. Market Revenue and Forecast (2022-2032)

9.1.2. Reproductive Health

9.1.2.1. Market Revenue and Forecast (2022-2032)

9.1.3. Other Therapeutic Application

9.1.3.1. Market Revenue and Forecast (2022-2032)

Chapter 10. US Liquid Biopsy Market, By Sample 

10.1. US Liquid Biopsy Market, by Sample, 2022-2032

10.1.1. Blood Sample

10.1.1.1. Market Revenue and Forecast (2022-2032)

10.1.2. Urine Sample

10.1.2.1. Market Revenue and Forecast (2022-2032)

10.1.3. Other

10.1.3.1. Market Revenue and Forecast (2022-2032)

Chapter 11. US Liquid Biopsy Market, By End User 

11.1. US Liquid Biopsy Market, by End User, 2022-2032

11.1.1. Hospitals and Laboratories

11.1.1.1. Market Revenue and Forecast (2022-2032)

11.1.2. Academic and Research Centers

11.1.2.1. Market Revenue and Forecast (2022-2032)

11.1.3. Other End Users

11.1.3.1. Market Revenue and Forecast (2022-2032)

Chapter 12. US Liquid Biopsy Market, Regional Estimates and Trend Forecast

12.1. U.S.

12.1.1. Market Revenue and Forecast, by Biomarker Types (2022-2032)

12.1.2. Market Revenue and Forecast, by Application (2022-2032)

12.1.3. Market Revenue and Forecast, by Sample (2022-2032)

12.1.4. Market Revenue and Forecast, by End User (2022-2032)

Chapter 13. Company Profiles

13.1. ANGLE plc, Biocept Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Bio-Rad Laboratories Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Epigenomics AG

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Exact Sciences Corporation

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. F. Hoffmann-La Roche AG

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Guardant Health Inc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Illumina Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. MDxHealth SA

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Menarini Silicon Biosystems

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. QIAGEN N.V.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

 

Post a Comment

0 Comments